NEW YORK (
CHANGE IN RATINGS, EPS
upgraded to buy at TheStreet ratings.
(AMD - Get Report)
upgraded at Wells from Market Perform to Outperform. Company is guiding toward better near-term growth.
target raised at Goldman to $53. Positive earnings call commentary. Maintain Buy rating.
price target raised at Goldman to $28. Costs saves a modest plus, but expect muted PM-USA profit in 2012. Neutral rating.
downgraded at UBS from Buy to Neutral. $20 price target. Major concerns about ability to execute and two SEC investigations.
estimates raised at Goldman through 2011 following through this quarter's upside. Maintain $47 price target and Buy rating.
Bristol Myers Squibb
target raised at UBS. BMY price target increased to $32. Launches still key, growth continues. Neutral rating.
(BG - Get Report)
estimates, target reduced at Credit Suisse. BG estimates were cut through 2012. Agribusiness profits will likely be lower than expected. Outperform rating and new $72 price target.
(CAM - Get Report)
estimates, target reduced at Credit Suisse. Shares of CAM now seen reaching $71. Estimates also cut, as the company is seeing slower growth in North America. Outperform rating.
estimates, target boosted at Credit Suisse. Shares of CERN now seen reaching $67. Higher sales are driving margin growth. Neutral rating.
(KO - Get Report)
rated new Buy at Deutsche. KO was initiated with a Buy rating. $75 price target. Growth potential remains highest in the emerging markets.
downgraded at Wells from Outperform to Market Perform. Admission rates have been hurt by Tenet's allegations.
downgraded at Jefferies from Hold to Underperform. $51 price target. Competitors are more attractive ways to play this sector.
numbers raised at Credit Suisse. Shares of DECK now seen reaching $122. Estimates also increased, as Ugg continues to drive growth. Outperform rating.
(DOW - Get Report)
estimates, target cut at Credit Suisse. DOW estimates were cut through 2012. Company is seeing lower demand across the board. Outperform rating and new $40 price target.
Dow Chemical estimates lowered at UBS through 2012. Third quarter was in line, but rough patch is coming. Maintain $38 price target and Buy rating.